Couverture de Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

Écouter gratuitement

Voir les détails

À propos de cette écoute

Joseph Mikhael, MD, and Saad Usmani, MD, discuss options in managing triple-class refractory multiple myeloma including selinexor, belantamab mafodotin, and CAR T-cell therapy.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964339). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Multiple Myeloma https://emedicine.medscape.com/article/204369-overview

Selinexor Prescribing Information https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf

Belantamab Mafodotin Prescribing Information https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Blenrep/pdf/BLENREP-PI-MG.PDF

Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview

Trending Clinical Topic: CAR T-cell Therapy https://reference.medscape.com/viewarticle/965011

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor https://www.karyopharm.com/wp-content/uploads/2020/06/Consensus-Recommendations_June2020.pdf

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932935/

Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Carfilzomib Nonrefractory Multiple Myeloma (MM) Patients. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8038

Ide-cel Prescribing Information https://packageinserts.bms.com/pi/pi_abecma.pdf

Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-label, Phase 2 Study https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(19)30788-0

DREAMM Trials https://dreammtrials.com/

Blenrep (Belantamab Mafodotin) REMS https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=403

Band Keratopathy https://emedicine.medscape.com/article/1194813-overview

Cilta-cel Prescribing Information https://www.fda.gov/media/156560/download

BCMA-Directed CAR T-cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT04318327
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !

    Ce que les auditeurs disent de Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

    Moyenne des évaluations utilisateurs. Seuls les utilisateurs ayant écouté le titre peuvent laisser une évaluation.

    Commentaires - Veuillez sélectionner les onglets ci-dessous pour changer la provenance des commentaires.

    Commentaires Audible.fr

    Commentaires Amazon
    Il n'y a pas encore de critique disponible pour ce titre.